| |
著者: Michał Zieliński, Piotr Wróblewski, Jerzy Kozielski
雑誌名: Adv Respir Med. 2019;87(3):184-188. doi: 10.5603/ARM.2019.0029.
Abstract/Text
Inhalation injury is a major cause of morbidity and mortality in patients with burns. Presence of airways injury adds to the need of fluid supplementation, increases risk of pulmonary complications. Due to many mechanisms involved in pathophysiology the treatment is complex. Among them the formation of fibrin casts inside airways constitutes a prominent element. The material residing in tracheobronchial tree causes ventilation-perfusion mismatch, complicates mechanical ventilation, provides a medium for bacterial growth. Many studies of animal models and single centre human studies investigated inhaled anticoagulation regimens employing heparin in management of inhalation injury. Simultaneously safety, especially in connection with possible bleeding risk, was the subject of research. The results suggest positive impact on treatment results, with low risk of side effects. This paper revise the available clinical data on inhaled heparin use in patients with burns.
PMID 31282560 Adv Respir Med. 2019;87(3):184-188. doi: 10.5603/ARM.2019.0029.
|
